Key Stats for Johnson & Johnson Stock
- 52-Week Range: $149 to $252
- Current Price: $233
- Street Mean Target: $253
- Street High Target: $285
- Analyst Consensus: 10 Buy, 5 Outperform, 8 Hold, 1 Underperform, 1 Sell
- TIKR Model Target (Dec. 2030): $325
J&J Beats Q1 Consensus and Raises Full-Year Guidance as ICOTYDE Launches at Speed
Johnson & Johnson (JNJ) reported first-quarter 2026 revenue of $24.06 billion, a 9.9% gain year-over-year, beating consensus and prompting management to raise full-year operational sales guidance to a range centered on $100.2 billion.
The STELARA biosimilar headwind was the story everyone expected, but J&J grew through it.
Excluding STELARA, the company grew at a double-digit rate in the quarter, a signal that the new product portfolio is absorbing the biosimilar impact faster than the market had assumed.
The oncology franchise led the way, with DARZALEX posting 17.8% growth and CARVYKTI growing 57.4% as site expansion continued.
ICOTYDE, the first oral IL-23 targeted peptide for plaque psoriasis, received FDA approval in March and launched the same day.
In the first weeks of commercialization, more than 1,500 patients had prescriptions written and more than 1,000 unique physicians had prescribed the drug.
TREMFYA continued to build on its immunology leadership, growing 63.8% in the quarter on the back of a strong inflammatory bowel disease launch.
In bladder cancer, INLEXZO received a permanent J-code for reimbursement, and J&J said new patient insertions jumped more than 50% in the first week after the code was issued and nearly 90% in the second week.
Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, described what followed in Q1 2026 earnings call:
“Following our J-code approval, which came at the beginning of April, what we saw in the first week was actually an over 50% increase in new patient insertions. And the second week that we have under our belt, we actually saw that jump up to almost 90% increase in new patient insertions.”
RYBREVANT FASPRO, the subcutaneous monthly formulation for EGFR-mutated non-small cell lung cancer, received FDA approval in January and reached $257 million in quarterly sales with growth of 80.5%.
MedTech delivered 4.6% operational growth, with Abiomed up 14.4% and Shockwave up 18.1%.
J&J also announced its 64th consecutive dividend increase, raising the quarterly payment to $1.34 per share.
Is Johnson & Johnson Stock a Buy? Wall Street Is Split — but the Growth Numbers Are Shifting the Debate
The market is asking a fair question about JNJ stock: does the new-product acceleration justify the current valuation, especially with talc litigation unresolved and biosimilar pressure on STELARA persisting into 2026?
Of 25 analysts tracked, 10 hold Buy ratings, 5 rate it Outperform, 8 are at Hold, 1 is at Underperform, and 1 is at Sell.
The Street’s mean target sits at around $253, roughly 9% above the current price.
Leerink Partners, which upgraded JNJ stock to Outperform in May and raised its target to around $265, frames the argument directly: strong new drug momentum in pharmaceuticals will drive accelerating revenue growth and stock outperformance.
The upgrade points specifically to ICOTYDE, INLEXZO, RYBREVANT, and TREMFYA as the products being underestimated by consensus models.
On the revenue trajectory, Wall Street projects J&J to report around $25 billion in Q2 2026 revenue, a roughly 5% year-over-year increase, with growth accelerating again in the back half of the year on the 53rd week benefit and continued new-product contribution.
EPS normalized came in at $2.70 in Q1 2026 and is estimated to reach around $2.85 in Q2, a roughly 3% year-over-year improvement.
The full-year adjusted EPS guidance of $11.30 to $11.50, raised from the prior range, puts annual per-share earnings on a growth trajectory as launch investments in the first half normalize.
JNJ stock’s revenue compounding argument is getting cleaner: the STELARA cliff was supposed to be the moment the model broke, and instead the company raised guidance.
CEO Joaquin Duato has stated explicitly that the double-digit growth target by the end of the decade is grounded in the existing, largely derisked portfolio and does not depend on M&A.
The bear case centers on talc litigation risk (over 67,000 plaintiffs), unresolved pricing pressure on Medicare drugs under the Inflation Reduction Act, and execution risk on a simultaneous multi-product launch cycle.
TIKR Values JNJ Stock at Around $325: Does the New-Product Pipeline Justify the Gap?
TIKR’s base case values Johnson & Johnson at approximately $325 by December 2030, implying around 40% total return from the current price of around $233, or roughly 8% annualized over approximately 4. and a half years.
If the new-product portfolio compounds at the low end — revenue growing around 6% annually, net margins near 30%, and EPS growing at roughly 7% per year — the model produces a stock price near $367, a roughly 58% total return, or around 5% annualized.
The mid case assumes around 7% revenue growth annually, net margins expanding toward approximately 32%, and EPS growing at around 9% per year, producing the $325 target and an annualized return near 8%.
In the high case, where ICOTYDE, INLEXZO, and RYBREVANT all inflect toward their peak sales potential faster than consensus expects, revenue growth runs near 8% annually, margins push toward approximately 33%, and EPS growth reaches around 10% per year, driving the stock toward around $568 — roughly double the current price over the full period, or roughly 11% annualized.
The condition that separates the scenarios is not whether the new drugs work: they already have regulatory approval and early commercial data. The condition is speed of adoption and breadth of indication expansion across ICOTYDE in IBD, INLEXZO in BCG-naive and BCG-exposed populations, and RYBREVANT in head and neck and colorectal cancer.
Is Johnson & Johnson stock a buy in 2026?
JNJ stock trades around $233 with a Leerink Outperform rating and a Street mean target near $253. TIKR’s base case points to approximately $325 by late 2030, around 40% above current price.
The near-term catalyst is ICOTYDE prescription volume data at the Q2 earnings call in July.
What is the price target for JNJ stock?
The Wall Street mean target for Johnson & Johnson stock is around $253, with the high target at around $285.
Leerink raised its target to approximately $265 in May after upgrading to Outperform, citing the drug launch pipeline as underestimated by consensus models.
Should You Invest in Johnson & Johnson?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Johnson & Johnson stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Johnson & Johnson alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JNJ stock on TIKR for Free →
